Drug Discovery

#Analysis #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Pathology #PCR #Protein chemistry / Proteomics #RNA #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Present and Future Challenges in Type 2 Diabetes

By Dr Lesley J Millatt, Dr Rmy Hanf and Dr Dean W Hum According to the International Diabetes Federation, more than 285 million people (6.4% of the world population) are currently estimated to suffer from diabetes, a figure which is expected to rise to 438 million (7.8%) by 2030. Moreover,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Molecular medicine #Pathology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Target validation #Toxicology #Translational #Translational chemistry

Utilising Biomarkers to Eliminate Drug Candidates with Cardiotoxicity in Preclinical Development

Utilising Biomarkers to Eliminate Drug Candidates with Cardiotoxicity in Preclinical Development By Dr Federica Crivellente The rapidly escalating costs of drug development is causing the biopharmaceutical industry to focus its R&D efforts on identifying new technologies and methods that can predict the safety and efficacy of new compounds as early… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Biomarkers #Business #Cell therapy #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Early Patient Stratification is Critical to Enable Effective and Personalised Drug Discovery and Development

Early Patient Stratification is Critical to Enable Effective and Personalised Drug Discovery and Development By Dr David A Fryburg, Dr Diane H Song and Dr David de Graaf With the current chances of an efficacious outcome in Phase II for novel mechanisms being in the region of 1 in 5,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #Imaging #Lead discovery #Lead optimisation #Oncology #PCR #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

In Vivo Preclinical Imaging – An Essential Tool in Translational Research

In Vivo Preclinical Imaging - An Essential Tool in Translational Research By Dr John Comley In vivo imaging of small animals (mainly mice) is increasingly being deployed across the drug development process, particularly in the oncology/cancer therapeutic area. One of the main applications is monitoring the treatment response for early… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Microfluidics #Organic chemistry #RNA #Screening #System biology #Systems biology #Therapeutics #Toxicology

Next Generation Flow Chemistry and Biology Platforms: The Impact on Small Molecule Drug Discovery

Next Generation Flow Chemistry and Biology Platforms: The Impact on Small Molecule Drug Discovery By Dr J Mark Treherne, Dr David M Parry and Christopher N Selway Can the next generation of flow chemistry and biology platforms be fully integrated to transform the efficiency of small-molecule drug discovery for pharmaceutical… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Business #Cell culture #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #Lead discovery #Molecular medicine #Patent Law #Preclinical #Regulatory #RNA #Sequencing #System biology #Systems biology #Target validation

What Are The Obstacles to Innovation in the Pharmaceutical Industry?

Share Share Tweet Email What Are The Obstacles to Innovation in the Pharmaceutical Industry? What Are The Obstacles to Innovation in the Pharmaceutical Industry? The Pistoia Alliance Innovation is a key word throughout the pharmaceutical industry and the healthcare community and its pursuit is a business imperative for Pharma. Pharma… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cell therapy #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

In Vivo Cell Reprogramming: Current status and potential clinical applications

In Vivo Cell Reprogramming: Current status and potential clinical applications By Dr Shili Wu, Jonathan Pang, Bobby Baravati, Jun Bao and Dr Yong Zhu In Vivo Cell Reprogramming, or IVR, is a new technology that can be used to develop cures for incurable diseases. Using a combination of protein, small… Read More

#Archive

#Academic #Animal models #Assay development optimisation & technology #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

3D Cell Culture Developments to Improve In Vitro Analyses

3D Cell Culture Developments to Improve In Vitro Analyses By Prof Stefan Przyborski Improved in vitro models are required to aid the identification and assessment of candidate molecules for pharmaceutical development. Conventional cell culture models involve the growth of cells on two-dimensional (2D) substrates. Cells adapt to this synthetic 2D… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #High throughput screening #Lead discovery #Oncology #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #Therapeutics #Toxicology

Enabling the Promise of Stem Cells

Enabling the Promise of Stem Cells By Robert Shaw and Dr Jeff Till The remarkable potential of stem cells to generate several hundred differentiated cell types is driving their use for regenerative medicine and for supporting the traditional drug discovery and development process (Figure 1). However, sustained progress in these… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Oncology #Orphan drugs #PCR #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

The Post Genomic Era: What Does It All Mean?

The Post Genomic Era: What Does It All Mean? By Dr Chris Torrance Information may no longer be a bottleneck to understanding and tackling complex genetic diseases such as cancer. For those who cut their research teeth not so very long ago, before PCR was thought of by Kary Mullis,… Read More

#Archive

#Analysis #Animal models #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #High Content Screening #Lead discovery #Oncology #Patent Law #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells

Regenerative Medicines: A Paradigm Shift in Healthcare

By Michael Werner, Morrie Ruffin and Elizabeth West The regenerative medicine market offers phenomenal opportunities for growth in the next few decades. However, there are still major issues to be addressed to enable this nascent industry to truly flourish, especially with regard to investment and the attitudes of regulatory agencies… Read More

#Archive

#Academic #Analysis #Assay development & optimisation #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genomics #High Content Screening #Imaging #Immunology / Virology & Vaccines #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Pathology #Pharmacogenomics #RNA #Screening #Sequencing #Therapeutics

The Future of Molecular Diagnostics For Cancer: A Personalised Approach

By Dr Cliff Murray Drug Discovery The pharmaceutical industry is still struggling to cure cancer despite pouring enormous resources into the search for new treatments. We take a look at the some of the current technologies for the discovery and delivery of molecular diagnostic, prognostic and predictive tests and speculate… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Oncology #PCR #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Epigenetics: An Emerging Target Class for Drug Screening

Epigenetics: An Emerging Target Class for Drug Screening By Dr John Comley Heightened awareness of the potential importance of epigenetic targets in many disease areas, and growing vendor interest in developing new assays to screen DNA methylation and histone modifications encouraged HTStec to undertake market research in this area in… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #PCR #Pharmokinetics #Preclinical #RNA #Screening #Stem cells #System biology

The Benefits Of Drug Repositioning

The Benefits Of Drug Repositioning By Dr Aris Persidis Drugs in development, on the market, or those that are shelved because of lack of efficacy, are excellent starting points for further development. Finding new indications for such drugs will benefit patients who will see a potential new therapy sooner, will… Read More

#Archive

#Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Immunology #Lead discovery #Oncology #Pharmokinetics #Regulatory #RNA

Balancing A Biologics Pipeline Portfolio

Balancing A Biologics Pipeline Portfolio By Dr Herren Wu Research into groundbreaking biologic therapies has significantly shifted the diagnosis and treatment paradigms for many disease categories, particularly in oncology, autoimmune, inflammation and neurology. Discovering and developing an innovative, first-in-class biologic has the potential to offer patients significant benefits as well… Read More

#Archive

#Business #Clinical specialities #Clinical trials #Drug development #Oncology #Orphan drugs #Regulatory

Making Early Access Real: getting treatments to patients with no other option

Making Early Access Real: getting treatments to patients with no other option By Dr Rav Seeruthun For patients who have no other option to treat their condition, early access to drugs in clinical development can be critical. As a trained physician, there is an intrinsic understanding that early access to… Read More

#Archive